Authors
Salmaan Kanji, María Patricia Hernández-Mitre, Hugues Blain, Neill K J Adhikari, Francois Lamontagne, Marie-Claude Battista, Julie Ménard, Sheila Sprague, Marie-Hélène Masse, Jason A Roberts, LOVIT Investigators
Published in
Clinical pharmacokinetics. Jun 22, 2026. Epub Jun 22, 2026.
Abstract
High-dose intravenous vitamin C was associated with increased harm in adults with sepsis requiring vasopressors in the large international LOVIT trial. This population pharmacokinetic sub-study of LOVIT aimed to characterise the pharmacokinetics of vitamin C and explore associations with patient characteristics and outcomes.
Patients who enrolled in the LOVIT trial were randomized to receive 50 mg/kg vitamin C every 6 hours for 96 hours or placebo. Blood samples were collected on study Days 1, 3, and 7 for plasma vitamin C quantification. Population pharmacokinetic modeling was performed, with relevant patient and treatment-related factors tested as covariates. Internal validation was conducted using bootstrap resampling (n = 1000). Univariable and multivariable analyses explored associations between 28-day mortality and patient characteristics, as well as the relationship between vitamin C exposure and severity of illness.
A total of 464 samples from 161 patients who were randomized to vitamin C were analysed. The median age was 64 (interquartile range [IQR] 56-72) years, weight 82 (IQR, 70-94) kg, and APACHE II score 24 (IQR, 18-29); 65.2% were male. A one-compartment model best described the data, with clearance (CL) significantly influenced by CKD-EPI eGFR and APACHE II score. Population mean estimates for clearance and volume of distribution were 3.37 L/h and 45.06 L, respectively. The model was internally validated and demonstrated to be robust and stable. Although greater vitamin C exposure was observed among non-survivors versus survivors (median 1900.5 [IQR 1191.8-2548.2] vs 1017.8 [IQR 630-1836.7] mg·h/L; p < 0.001), only age (odds ratio [OR] 1.063; 95% confidence interval [CI] 1.024-1.104, p = 0.001) and APACHE II score (OR 1.079; 95% CI 1.005-1.158, p = 0.036) were independently associated with 28-day mortality. Severity of illness was also predictive of vitamin C exposure.
Vitamin C pharmacokinetics are highly variable between individuals. Some of this variability can be explained by changes in glomerular filtration and APACHE II score as a measure of illness severity. Although non-survivors had greater vitamin C exposure than survivors, exposure was not independently associated with mortality.
PMID:
42329551
Bibliographic data and abstract were imported from PubMed on 22 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0